Press release
Investigation announced for Long-Term Investors in shares of Teligent Inc (NASDAQ: TLGT)
An investigation on behalf of current long term investors in Teligent Inc (NASDAQ: TLGT) shares.
Investors who are current long term investors in Teligent Inc (NASDAQ: TLGT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: TLGT stocks follows a lawsuit filed against Teligent Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: TLGT stocks, concerns whether certain Teligent directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the Defendants made false and/or misleading statements regarding, and/or failed to disclose, product non-conformities in research and development and non-compliance with applicable regulations.
Those who purchased shares of Teligent Inc (NASDAQ: TLGT) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Teligent Inc (NASDAQ: TLGT) here
News-ID: 1830338 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Teligent
Lidocaine Ointment Market Is Booming So Rapidly 2025-2032 -Glenmark Pharmaceutic …
Latest Qualitative Research Report on the Lidocaine Ointment Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research explores into the evolving Market's dynamics, value chain analysis, prominent investment areas, competitive landscape, drivers and constraints, regional outlook, and key market segments. It's also provides the industry overview with growth analysis and historical…
Lidocaine Ointment Market Growth, Scope and Business Opportunities 2025-2032 | G …
The Latest study titled Lidocaine Ointment Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the report…
Lidocaine Ointment Market to Hit Substantial Growth | Demand, Share & Future Out …
The global Lidocaine Ointment Market is expected to grow at 7.7% CAGR from 2025 to 2032.
The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for Global Lidocaine Ointment Market 2025" provides a sorted image of the Lidocaine Ointment Market industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to…
Lidocaine Ointment Market Overall Study Report 2024-2031 | Glenmark Pharmaceutic …
The Latest study titled Lidocaine Ointment Market 2024, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2024 to 2031. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the report…
Cefuroxime Sodium Injection Market Detailed Analysis of Current Industry Figures …
Complete study of the global Cefuroxime Sodium Injection market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Cefuroxime Sodium Injection industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They…
Erythromycin Market Challenges with Forecast top key players Ani Pharmaceuticals …
Erythromycin is an antibiotic, which is used to treat certain kind of bacterial infections. Erythromycin topical preparations are largely used on the skin to help control acne. The antibiotic is also used in combination with other medicines and are applied topically or taken orally for treating the infections.
The common side effects of erythromycin include nausea, loss of appetite, diarrhea, and abdominal pain. Erythromycin prevents bacterial cells from growing and…
